Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SPD's Beck wants measured approach to stem cell law review

This article was originally published in Clinica

Executive Summary

The head of German's SPD party, Kurt Beck, has rejected calls by the German research society (DFG) for a rapid liberalisation of the law on stem cell research. "This would be the wrong way to go," he said in an interview published by Rheinisch Merkur, indicating that the associated ethical issues warrant a considered approach to any review of the law. He advocated a bolder policy for the use of stem cell therapies in the most seriously ill, however. But his fundamental views have set him on a collision course with Chancellor Angela Merkel, who has expressly asked the scientific community to offer ideas that can serve as the basis for an overhaul of Germany's stem cell legislation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT053584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel